Huang Zhen, Wang Sheng-Lin, Huang Qing-Shan, Li Xiao-Dong, Chen Hui, Lin Jian-Hua
Department of Orthopedics, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Fujian Provincial Institute of Orthopedic, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Acta Orthop Traumatol Turc. 2020 Jan;54(1):34-41. doi: 10.5152/j.aott.2020.01.484.
The aim of this study was to investigate ErbB2 expression in osteochondroma and its relationship with clinicopathologic features of osteochondroma, so as to identify a new biomarker for the malignant transformation potential of osteochondroma.
Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to investigate the expression status of ErbB2 protein and gene in 30 osteochondroma tissues and 20 non-neoplastic bone tissues. The association of ErbB2 gene and protein expression with clinicopathological parameters of osteochondroma was analyzed by using the χ2 test and Fishers exact test.
ErbB2 protein was found to be over-expressed in 4 of 30 (13.3%) osteochondromas and 1 of 20 (5%) non-neoplastic bone samples, which were not statistically significant (p=0.336). However, 13 of the 30 (43.3%) osteochondromas showed ErbB2 gene amplification, which was failed to be observed in any of the non-neoplastic bone tissue. ErbB2 gene amplification in osteochondroma was significantly higher compared with that in non-neoplastic bone tissue (p=0.001). In addition, the ErbB2 gene amplification was closely associated with clinical pathological parameters of osteochondroma, including high expression of cellularity (p=0.001), presence of binucleated cells (p=0.001), nuclear pleomorphism (p=0.003), calcification (p=0.002), nodularity (p=0.002), necrosis (p=0.009) and cartilage thickness (p=0.026). The association of the gene amplification with other clinicopathological parameters of osteochondroma, including permeation of trabecular bone, cystic/mucoid changes, mitosis, radiographic appearance, cap volume and subtype of osteochondroma was not observed. The over-expression of ErbB2 protein was not found to be associated with the above stated clinical pathological parameters of osteochondroma.
ErbB2 gene amplification was associated with adverse clinicopathological status of osteochondroma and could serve as an index for malignant conversion of osteochondroma. Further research is required to verify the predictive values of ErbB2 for osteochondroma.
Level IV, Diagnostic Study.
本研究旨在探讨ErbB2在骨软骨瘤中的表达及其与骨软骨瘤临床病理特征的关系，以确定一种用于评估骨软骨瘤恶变潜能的新生物标志物。
采用免疫组织化学（IHC）和荧光原位杂交（FISH）技术，检测30例骨软骨瘤组织和20例非肿瘤性骨组织中ErbB2蛋白和基因的表达情况。运用χ2检验和Fisher精确检验分析ErbB2基因和蛋白表达与骨软骨瘤临床病理参数的相关性。
在30例骨软骨瘤中有4例（13.3%）、20例非肿瘤性骨样本中有1例（5%）检测到ErbB2蛋白过表达，但差异无统计学意义（p = 0.336）。然而，30例骨软骨瘤中有13例（43.3%）显示ErbB2基因扩增，而在任何非肿瘤性骨组织中均未观察到。骨软骨瘤中ErbB2基因扩增显著高于非肿瘤性骨组织（p = 0.001）。此外，ErbB2基因扩增与骨软骨瘤的临床病理参数密切相关，包括细胞丰富度高表达（p = 0.001）、双核细胞存在（p = 0.001）、核异型性（p = 0.003）、钙化（p = 0.002）、结节状（p = 0.002）、坏死（p = 0.009）和软骨厚度（p = 0.026）。未观察到基因扩增与骨软骨瘤其他临床病理参数的相关性，包括小梁骨浸润、囊性/黏液样改变、有丝分裂、影像学表现、帽体积和骨软骨瘤亚型。未发现ErbB2蛋白过表达与上述骨软骨瘤临床病理参数相关。
ErbB2基因扩增与骨软骨瘤不良临床病理状态相关，可作为骨软骨瘤恶变的指标。需要进一步研究以验证ErbB2对骨软骨瘤的预测价值。
IV级，诊断性研究。
